Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
about
Relevance of tumor-infiltrating lymphocytes in breast cancerCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerQuantification of HER family receptors in breast cancerA perspective on anti-EGFR therapies targeting triple-negative breast cancerA phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis.Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapyAnti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.Recent development of targeted approaches for the treatment of breast cancer.Basis for molecular diagnostics and immunotherapy for esophageal cancer.Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer.MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges.Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer.How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies.Immunotherapeutic interventions of Triple Negative Breast Cancer.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancerThe paradoxical functions of EGFR during breast cancer progression
P2860
Q26795598-F9087BDB-4C8B-4FAE-8A57-B509596E180EQ26798074-AFE249D8-4EEB-4F61-9B2D-0D0E086A880CQ27015506-AD0A5E4E-9B05-4184-987F-E405966CCB91Q28069867-31EC1A77-F9C5-4733-9EB8-2B3C5D200351Q33422448-31BC4B04-8D31-459A-A060-1DCC691B8969Q36097941-98E9A5F2-B5BC-42BB-8AEE-B7E465111FFFQ37316603-FC511E7A-4D0F-4A73-87AB-F60F0390253FQ37536862-45B9BB44-5BCC-4D38-B3C1-8F4D4603D644Q37687445-287FC875-4234-41A2-B3FF-292627D8B098Q38686046-9CDE978C-2B27-4F01-92FF-482B0D03C05DQ38730179-BC05D5B5-81C7-45C2-9C5A-DF081D6E71D1Q38802191-4EB8E6A4-E670-491F-A41A-5B7A4B53A219Q39006844-07E8BD99-9A0E-4846-9BD1-75D90FC2D4DEQ39167876-65EBF9C8-2984-47A6-A77A-0A495CF8C803Q44378342-612B20F2-BF46-4F70-A175-4AF1CFE28DF3Q47863345-8BC66DF8-3C0E-403E-BF09-6A59A1AF44F5Q48263230-33C855D9-AA09-4AE2-9B56-EEFB1E780B13Q48850918-D765321C-15D7-4DA0-8AE3-FF551E6600DEQ49303842-E07A1E69-81F2-40E0-BFDF-57558FC81CA2Q49887925-D48C7DC5-067C-458F-96B6-2C84420F8EF7Q50042972-9F9DF694-5364-40EC-B861-373EB94FDABCQ50068205-E4B0DAFF-25B9-4C0D-952D-1300C55BBAECQ53805931-A2E4079A-4BA4-447F-A2C1-48595A222D38Q54965602-C58D67D2-D131-412E-B9C2-02B8F2323FBCQ55257180-CBD9AFC7-2B48-44A6-8471-D75D03EECFAEQ57105411-D01B6E52-78FC-4C71-A5A6-6B43FE839850Q57118645-DB19CF96-643A-447B-B8D4-D332830046CC
P2860
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
description
im Mai 2014 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 14 May 2014
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2014
@uk
name
Multicentric neoadjuvant phase ...... es predicting treatment impact
@en
Multicentric neoadjuvant phase ...... es predicting treatment impact
@nl
type
label
Multicentric neoadjuvant phase ...... es predicting treatment impact
@en
Multicentric neoadjuvant phase ...... es predicting treatment impact
@nl
prefLabel
Multicentric neoadjuvant phase ...... es predicting treatment impact
@en
Multicentric neoadjuvant phase ...... es predicting treatment impact
@nl
P2093
P2860
P50
P356
P1433
P1476
Multicentric neoadjuvant phase ...... es predicting treatment impact
@en
P2093
A Desrichard
A M Forest
C Jouannaud
F Kwiatkowski
F Penault-Llorca
I Van Praagh
J M Nabholtz
K E Benmammar
M A Mouret-Reynier
P2860
P304
P356
10.1093/ANNONC/MDU183
P577
2014-05-14T00:00:00Z